← Back to Screener
Savara Inc. (SVRA)
Price$5.09
Value ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-27.00%
Price vs S&P 500 (4W)-2.67%
VGM Score35.20
Market Capitalization$1.04B
All Metrics
Book Value / Share (Quarterly)$0.86
P/TBV (Annual)6.41x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.52
Price vs S&P 500 (YTD)-23.75%
Net Profit Margin (TTM)-4253.85%
EPS (TTM)$-0.56
10-Day Avg Trading Volume1.54M
EPS Excl Extra (TTM)$-0.56
EPS (Annual)$-0.48
ROI (Annual)-48.47%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-11537.00%
Cash / Share (Quarterly)$0.99
ROA (Last FY)-45.10%
EBITD / Share (TTM)$-0.58
ROE (5Y Avg)-47.43%
Operating Margin (TTM)-4150.00%
Cash Flow / Share (Annual)$-0.49
P/B Ratio5.93x
P/B Ratio (Quarterly)6.35x
Net Income / Employee (Annual)$-1,371,400
EV / Revenue (TTM)3978.29x
Net Interest Coverage (TTM)-345.82x
ROA (TTM)-66.42%
EPS Incl Extra (Annual)$-0.48
Current Ratio (Annual)11.85x
Quick Ratio (Quarterly)13.22x
3-Month Avg Trading Volume1.53M
52-Week Price Return113.87%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.80
P/S Ratio (Annual)4011.84x
Asset Turnover (Annual)0.00x
52-Week High$7.00
Operating Margin (5Y Avg)-11595.18%
EPS Excl Extra (Annual)$-0.48
CapEx CAGR (5Y)-63.27%
Tangible BV CAGR (5Y)29.74%
26-Week Price Return-19.08%
Quick Ratio (Annual)11.68x
13-Week Price Return-7.29%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)13.47x
Enterprise Value$1.03B
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-3.49%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-19084.62%
Cash / Share (Annual)$1.15
3-Month Return Std Dev49.93%
Net Income / Employee (TTM)$-1,849,700
ROE (Last FY)-55.99%
Net Interest Coverage (Annual)-18.37x
EPS Basic Excl Extra (Annual)$-0.48
Total Debt / Equity (Quarterly)0.17x
EPS Incl Extra (TTM)$-0.56
ROI (TTM)-72.59%
P/S Ratio (TTM)4011.84x
Pretax Margin (5Y Avg)-11907.77%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.94
Price vs S&P 500 (52W)89.50%
Year-to-Date Return-15.59%
5-Day Price Return-1.17%
EPS Normalized (Annual)$-0.48
ROA (5Y Avg)-35.67%
Net Profit Margin (Annual)-19084.62%
Month-to-Date Return-2.12%
Cash Flow / Share (TTM)$-0.31
EBITD / Share (Annual)$-0.52
Operating Margin (Annual)-18961.54%
LT Debt / Equity (Annual)0.15x
ROI (5Y Avg)-38.10%
LT Debt / Equity (Quarterly)0.17x
EPS Basic Excl Extra (TTM)$-0.56
P/TBV (Quarterly)6.79x
P/B Ratio (Annual)6.04x
Pretax Margin (TTM)-4253.85%
Book Value / Share (Annual)$0.99
Price vs S&P 500 (13W)-15.54%
Beta0.31x
Revenue / Share (TTM)$0.00
ROE (TTM)-87.19%
52-Week Low$1.98
vGradeF
mGradeB
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.15est. -0.14
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SVRASavara Inc. | F | — | B | $5.09 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Savara Inc. is a specialty pharmaceutical company developing treatments for rare respiratory diseases. Its lead program, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).